Inhibrx Biosciences, Inc. (INBX) vs Taysha Gene Therapies, Inc. (TSHA)

Inhibrx Biosciences, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.6B and $1.5B). Across the 10 metrics below, Taysha Gene Therapies, Inc. leads on 7 and Inhibrx Biosciences, Inc. on 3.

Valuation

Metric INBX TSHA Biotechnology median
P/E n/m n/m 7.88
P/S 495.33 146.12 11.47
P/B n/m 4.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 508.96 111.68 10.73
Earnings yield (8.91%) (8.99%) (28.84%)
Free cash flow yield (8.45%) (8.07%) (23.03%)

Profitability

Metric INBX TSHA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (1,773.60%) (47.05%) (57.72%)
Return on assets (75.44%) (37.23%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INBX TSHA Biotechnology median
Revenue growth (TTM) — 18.96% 5.64%
EPS growth (last fiscal year) (108.03%) 5.56% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric INBX TSHA Biotechnology median
Debt to equity (3.33) 0.13 0.00
Current ratio 5.07 17.76 4.73
Net debt to EBITDA 0.18 2.47 0.96

Dividend

Metric INBX TSHA Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric INBX TSHA Biotechnology median
Market cap 1.48b 1.56b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack